Finoriq research workspace
Beta Bionics, Inc. (BBNX) SEC Filings & Filing Highlights
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design. Review BBNX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
- Company
- Beta Bionics, Inc. (BBNX)
- Ticker
- BBNX
- Market Cap
- $799.7M
- Latest Price
- $17.95
- Industry
- Medical Devices
Beta Bionics, Inc. (BBNX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Beta Bionics, Inc. (BBNX).
| Event | Form | Date |
|---|---|---|
| On May 21, 2026, Beta Bionics, Inc. held its 2026 Annual Meeting of Stockholders. The Company’s...On May 21, 2026, Beta Bionics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Company’s defi... | 8-K5.07 | 2026-05-22 |
| Beta Bionics, Inc.: Corporate updateOn May 21, 2026, the Company announced that it expects to fully commercialize Mint by the end of the second quarter of 2027, subject to reg... | 8-K8.01 | 2026-05-21 |
| On May 21, 2026, Beta Bionics, Inc. issued a press release announcing updated timeline expectat...On May 21, 2026, Beta Bionics, Inc. (the “Company”) issued a press release announcing updated timeline expectations for the commercializati... | 8-K7.01 | 2026-05-21 |
| Beta Bionics, Inc.: Earnings or resultsOn April 21, 2026, Beta Bionics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended M... | 8-K2.02 | 2026-04-21 |
| Beta Bionics, Inc.: Earnings or resultsOn February 17, 2026, Beta Bionics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and... | 8-K2.02 | 2026-02-17 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.